Higher relative survival in breast cancer patients treated in certified and high-volume breast cancer centres - A population-based study in Belgium.

Breast cancer Certification Quality of care Survival Volume-outcome analyses

Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
20 Jul 2024
Historique:
received: 18 04 2024
accepted: 09 07 2024
medline: 6 9 2024
pubmed: 6 9 2024
entrez: 5 9 2024
Statut: aheadofprint

Résumé

The study was undertaken to assess the association between certification and volume of breast centres on the one hand and survival on the other in patients with invasive breast cancer (IBC). The study comprises a cohort of 46,035 patients diagnosed with IBC between 2014 and 2018, selected from the nation-wide Belgian Cancer Registry (BCR) database, which was linked with health insurance, hospital discharge and vital status data. Overall and relative survival probabilities were obtained with Kaplan-Meier method and an actuarial approach based on Ederer II, respectively. The associations between centre certification/volume and relative survival were assessed using Poisson models, adjusted for potential confounders. Five years after the diagnosis of IBC, the observed and relative survival probabilities for the cohort were 83.4 % (95 %CI: [83.1, 83.8]) and 93.3 % (95 %CI: [92.9, 93.7]), respectively. After adjustment for age and combined tumour stage, the risk to die from BC was 44 % higher (EHR: 1.44, 95 %CI: [1.24, 1.66]) for patients treated in a low-volume centre and 30 % higher (EHR: 1.30, 95 %CI: [1.14, 1.48]) for patients treated in a medium-volume centre, compared to high-volume centres. Likewise, the risk to die from BC was 30 % higher (EHR: 1.30, 95 %CI: [1.15, 1.48], p < 0.001) for patients treated in a non-certified centre (representing 23.8 % of the cohort), compared to patients treated in a coordinating breast clinic. This population-based study reveals that BC survival is higher when patients are treated in certified and high-volume breast clinics.

Identifiants

pubmed: 39236426
pii: S0959-8049(24)00888-8
doi: 10.1016/j.ejca.2024.114232
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114232

Informations de copyright

Copyright © 2024 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Roos Leroy (R)

Belgian Health Care Knowledge Centre (KCE), Brussels, Belgium. Electronic address: roos.leroy@kce.fgov.be.

Geert Silversmit (G)

Belgian Cancer Registry (BCR), Brussels, Belgium.

Jolyce Bourgeois (J)

Belgian Health Care Knowledge Centre (KCE), Brussels, Belgium.

Cindy De Gendt (C)

Belgian Cancer Registry (BCR), Brussels, Belgium.

Isabelle Savoye (I)

Belgian Health Care Knowledge Centre (KCE), Brussels, Belgium.

Julie Verbeeck (J)

Belgian Cancer Registry (BCR), Brussels, Belgium.

Nancy Van Damme (N)

Belgian Cancer Registry (BCR), Brussels, Belgium.

Sabine Stordeur (S)

Federal Public Service Health, Food Chain Safety and Environment, Brussels, Belgium.

Jean-Luc Canon (JL)

Department of Medical Oncology, Grand Hôpital de Charleroi, Charleroi, Belgium.

Birgit Carly (B)

Breast Clinic Isala, CHU St Pierre, Brussels, Belgium.

Pino G Cusumano (PG)

Department of Senology, Liège University Hospital, University of Liège, Liège, Belgium.

Evandro de Azambuja (E)

Department of Medical Oncology, Institute Jules Bordet and l'Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.

Pieter De Visschere (P)

Department of Radiology and Nuclear Medicine, Ghent University Hospital, Ghent, Belgium.

Jan Decloedt (J)

Department of Senology, AZ Sint-Blasius, Dendermonde, Belgium.

Joëlle Desreux (J)

Department of Obstetrics and Gynaecology, CHU Liège, Liège, Belgium.

Francois P Duhoux (FP)

Department of Medical Oncology, King Albert II Cancer Institute, Cliniques universitaires Saint-Luc, Brussels, Belgium.

Donatienne Taylor (D)

Department of Medical Oncology, CHU UCL Namur Clinique Sainte, Elisabeth, Namur, Belgium.

Peter van Dam (P)

Department of Gynaecologic Oncology, Antwerp University Hospital, Edegem, Belgium.

Ilse Vanhoutte (I)

Department of Radiation Oncology, AZ Sint-Lucas, Ghent, Belgium.

Liv Veldeman (L)

Department of Radiation Oncology, Ghent University Hospital/Department of Human Structure and Repair, Ghent University, Ghent, Belgium.

Hans Wildiers (H)

Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.

Classifications MeSH